Company intelligence / Profile preview

NeoLumina

Bedminster, New Jersey, United States

Ownership: Private
Development stage: Other

Overview

NeoLumina Bioscience is a biotechnology company specializing in the development of next-generation radiopharmaceuticals for the treatment of cancer. The company utilizes a theranostic approach, combining diagnostic imaging with targeted radionuclide therapy to improve patient outcomes. Its lead program, NLM-001, is a Lutetium-177 labeled radioligand targeting prostate-specific membrane antigen (PSMA) for metastatic castration-resistant prostate cancer. NeoLumina aims to overcome the limitations of current radiotherapies by optimizing ligand design for better tumor uptake and reduced off-target toxicity. The company is led by industry veterans with significant experience in radiopharmaceutical development and oncology.

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalSmall molecule
Industry: Biotech

Beyond the preview

Go deeper on NeoLumina.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeoLumina.

Explore the full profile